載入...
RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
RRx-001 is a pleiotropic anticancer agent in phase III clinical trials, which polarizes tumor-associated macrophages from a low phagocytic M2 phenotype to a high phagocytic M1 phenotype. One of the ways in which tumors promote M2 polarization and evade macrophage-mediated destruction is through upre...
Na minha lista:
| 發表在: | Transl Oncol |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Neoplasia Press
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6370857/ https://ncbi.nlm.nih.gov/pubmed/30738349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2018.12.001 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|